About
The U.S. government spends billions of dollars per year on the purchase of drugs making it one of the largest purchasers of pharmaceuticals in the U.S. Sales to the government typically account for a large portion of a company’s total revenue, and a company cannot remain competitive in today’s market without selling to the government. As pharmaceutical manufacturers’ revenue and profits are so closely tied to government contracts and pricing, it is essential to have a thorough understanding of the Veterans Health Care Act, Federal Supply Schedule Contracting, Federal Ceiling Price, and pharmacy benefits programs.
While having the government as a client is lucrative, it can be costly, time consuming and confusing. Understanding the basics and key terms of “Big Four” pricing is necessary to ensure that companies do not enter into price contracts that obligate them to comply with impossible terms. Selling to the VA, DoD, PHS and Coast Guard also requires constant price calculations and price reporting. These calculations are often perplexing and result in price anomalies that can leave even the most seasoned pricing practitioner baffled. On top of complying with the “Big Four’s” numerous rules and regulations, companies must also evaluate how their “Big Four” prices affect their overall pricing.
Master the essentials of key “Big Four” pricing concepts and methodologies
ACI’s “Big Four” Pharmaceutical Pricing Boot Camp has been designed to give novices and experienced practitioners alike a complete understanding of core pricing competencies. ACI has assembled a faculty of the government authorities on “Big Four” pricing and pharmacy benefits programs along with expert pricing practitioners. This distinguished faculty will make sense of complicated terminology and pricing calculations and teach you how to navigate the complexities of working with the “Big Four” agencies. Also hear the latest information on legislative proposals/changes that may impact the 340B program and TRICARE rebates.
About
The U.S. government spends billions of dollars per year on the purchase of drugs making it one of the largest purchasers of pharmaceuticals in the U.S. Sales to the government typically account for a large portion of a company’s total revenue, and a company cannot remain competitive in today’s market without selling to the government. As pharmaceutical manufacturers’ revenue and profits are so closely tied to government contracts and pricing, it is essential to have a thorough understanding of the Veterans Health Care Act, Federal Supply Schedule Contracting, Federal Ceiling Price, and pharmacy benefits programs.
While having the government as a client is lucrative, it can be costly, time consuming and confusing. Understanding the basics and key terms of “Big Four” pricing is necessary to ensure that companies do not enter into price contracts that obligate them to comply with impossible terms. Selling to the VA, DoD, PHS and Coast Guard also requires constant price calculations and price reporting. These calculations are often perplexing and result in price anomalies that can leave even the most seasoned pricing practitioner baffled. On top of complying with the “Big Four’s” numerous rules and regulations, companies must also evaluate how their “Big Four” prices affect their overall pricing.
Master the essentials of key “Big Four” pricing concepts and methodologies
ACI’s “Big Four” Pharmaceutical Pricing Boot Camp has been designed to give novices and experienced practitioners alike a complete understanding of core pricing competencies. ACI has assembled a faculty of the government authorities on “Big Four” pricing and pharmacy benefits programs along with expert pricing practitioners. This distinguished faculty will make sense of complicated terminology and pricing calculations and teach you how to navigate the complexities of working with the “Big Four” agencies. Also hear the latest information on legislative proposals/changes that may impact the 340B program and TRICARE rebates.
Contents & Contributors
Overview of the “Big Four” and the Veterans Health Care Act (VHCA)
Melbourne A. Noel, Jr., Department of Veteran Affairs
Marci Anderson, VA Office of Inspector General, Office of Contract Review
VHCA §603: Calculating the Non-FAMP and the Federal Ceiling Price (FCP)
Joy E. Sturm, Hogan & Hartson LLP
Marci Anderson, VA Office of Inspector General, Office of Contract Review
Melbourne A. Noel, Jr., Department of Veteran Affairs
John D. Shakow, King & Spalding
FSS Contracting for the Pharmaceutical Industry: Exploring the Federal Supply Schedule
Maureen Regan, VA Office of Inspector General
Interacting With the VA and Understanding the Agency’s Structure
Maureen Regan, VA Office of Inspector General
Marci Anderson, VA Office of Inspector General, Office of Contract Review
Effectively Managing the Negotiation Process
W. R. (Bob) Satterfield, III, VA Office of Acquisition & Logistics
Christine A. Szrom, VA Office of Acquisition & Logistics
Government fss Programs
Marci Anderson, VA Office of Inspector General, Office of Contract Review
Maureen Regan, VA Office of Inspector General
Merle M. DeLancey Dickstein Shapiro LLP
Single versus Dual Pricing
Marci Anderson, VA Office of Inspector General, Office of Contract Review
Background to the New TRICARE Rule
Melbourne A. Noel, Jr., Department of Veteran Affairs
TRICARE Rx Program
Carol Cooper, TRICARE Management Activity
TRICARE: A Study in the DoD’s Managed Health Care Benefits Program and Update on TRICARE Rebates
Constance A. Wilkinson, Epstein Becker & Green, P.C.
340B Program Fundamentals
Debjit A. Ghosh, Huron Consulting Group
Benjamin S. Martin, Epstein Becker & Green, P.C.
William von Oehsen, Safety Net Hospitals for Pharmaceutical Access
Demystifying the DoD Uniform Formulary
Allison D. Pugsley, Hogan & Hartson LLP, VA formulary management
Vincent Calabrese, Pharmacy Benefits Management Services
Strategies for Securing National Contracts and Blanket Purchase Agreements
Steven A. Thomas, Department of Veterans Affairs
All new all improved? bpa’s & national contracts;
Larry Allen, Coalition for Government Procurement
Audit Rights, Record Retention and Penalties
Maureen Regan, VA Office of Inspector General
T. Reed Stephens, McDermott Will & Emery LLC
Publication Details